{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-063523","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.066295+00:00","generated_at":"2026-05-22T18:46:55.375001+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Biomea Fusion Q1 loss $29.3M; realigns on diabetes/obesity, cuts workforce 35%","bullets":["Q1 net loss $29.3M ($36.2M cash); cash runway extended into Q4 2025.","Strategic realignment: 35% workforce reduction; focus on icovamenib and oral GLP-1 BMF-650.","R&D expenses $22.9M (down from $33.8M YoY); G&A $6.8M (down from $7.3M).","Phase II COVALENT-111 52-week T2D data expected H2 2025; Type-C meeting with FDA planned.","Interim CEO Mick Hitchcock appointed March 2025; oncology BMF-500 partnership exploration."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-063523","json":"https://secwatch.observer/filing/0000950170-25-063523.json","markdown":"https://secwatch.observer/filing/0000950170-25-063523.md","text":"https://secwatch.observer/filing/0000950170-25-063523.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000095017025063523/0000950170-25-063523-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000095017025063523/bmea-20250505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T18:46:55.375001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}